|
INTRODUCTION
In the absence of pipeline compounds that can exceed the efficacy of statins, a number of trends have been identified. Pipeline developments are
focusing on therapies that target lipid parameters inadequately controlled with statins, adjunctive therapies with novel mechanisms of action and
statin/non-statin anti-dyslipidemic and statin/non anti-dyslipidemic single pill combinations
SCOPE OF THE REPORT
- Determination of the size of the hypercholesterolemia population in the seven major markets and summarization of the prevalence of low HDL
cholesterol
- Quantitative overview of product development by class and phase to assess competitor activity and licensing opportunities
- In-depth analysis of clinical and market factors for late-stage statin and non-statin developmental therapies, including sales forecasts to 2011
- Overview of innovative early stage therapies, identifying promising development strategies and programs
REPORT HIGHLIGHTS
Although statins will continue to dominate the market, these drugs have been plagued by safety concerns, which have delayed the approval of both
Crestor and Livalo. The dyslipidemia R&D pipeline consists of 15 novel classes and increased availability of adjunctive therapies will lead to
vast improvements in the treatment of more 'difficult-to-treat' patients. Following greater acceptance of combination therapy, current developments
are focusing on multi-modal therapies and statin single pill combinations.
KEY REASONS OT BUY THIS REPORT
- Recognize key areas within the current treatment of dyslipidemia that are inadequately served
- Gain an independent view of the R&D activity in the market
- Determine the gaps in the market, in order to position developmental products, and identify lucrative licensing and co-marketing opportunities
| 
View Cart
